FDA to discuss easing restrictions on peptides despite safety concerns

In July, FDA advisers will debate relaxing limits on peptides, drugs with limited safety and efficacy evidence, despite concerns. If restrictions are lifted, US pharmacies could legally produce these peptides, potentially broadening access for Americans. This move could significantly impact the market and public health, given the lack of robust clinical data backing their use. The discussion underscores the tension between innovation and safety in drug regulation.